FDA Rejects Nasal Opioid Overdose Treatment

Feb 21, 2017

The U.S. Food and Drug Administration has rejected Amphastar Pharmaceuticals's application to market an intranasal version of its emergency opioid-overdose treatment.

The FDA identified issues with the user interface of the treatment. Amphastar sells the treatment, naloxone, in prefilled syringes. Kaleo Pharmaceuticals recently received criticism for raising the price of its naloxone device Evzio by 550 percent.

According to a Reuters report, Adapt Pharma has two nasal spray formulations approved by the U.S. FDA.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments